Standard BioTools Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LAB research report →
Range $3.25 – $3.25
Price Chart
About the company
Standard BioTools Inc. , together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments.
- CEO
- Michael Egholm
- IPO
- 2011
- Employees
- 387
- HQ
- Boston, MA, US
Get TickerSpark's AI analysis on LAB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $249.11M
- P/E
- -5.74
- PEG
- -0.08
- P/S
- 2.95
- P/B
- 0.45
- EV/EBITDA
- -0.11
- Div Yield
- 0.00%
- Gross Margin
- 50.82%
- Op Margin
- -90.60%
- Net Margin
- -46.44%
- ROE
- -7.54%
- ROIC
- -6.61%
Latest fiscal year · YoY change
- Revenue
- $85.33M-51.1%
- Gross Profit
- $42.54M-49.5%
- Op Income
- $-93,305,000
- Net Income
- $-74,896,000+46.1%
- EPS
- $-0.20+61.5%
- OCF Growth
- +48.2%
- FCF Growth
- +45.6%
- 52W High
- $1.72
- 52W Low
- $0.39
- 50D MA
- $0.67
- 200D MA
- $0.86
- Beta
- 1.35
- RSI (14)
- 49
- Avg Volume
- 1.18M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Standard BioTools said Q1 was in line with plan, with revenue down 10% year over year but margin and cash burn improving as it keeps full-year guidance unchanged.· May 6, 2025
- Q1 revenue was $40.8 million, down 10% year over year, and management said results were in line with expectations.
- Non-GAAP gross margin was 53.2% versus 56.2% last year, pressured by lower volume, lower service pricing, and mix.
- Non-GAAP operating expenses fell 22% year over year to $38.6 million after another $10 million annualized cost reduction.
- Adjusted EBITDA loss improved to $16.9 million from $23.7 million, and total cash burn dropped sharply to $34 million.
- Full-year 2025 revenue guidance stayed at $165 million to $175 million, with the year expected to be back-half weighted.
Q1 2025 revenue was $40.8 million, down 10% year over year. Non-GAAP gross margin was 53.2% versus 56.2% in Q1 2024. Non-GAAP operating expenses were $38.6 million, down $10.7 million, or 22% year over year. Net loss was $26 million versus $32.2 million last year, and adjusted EBITDA loss was $16.9 million versus $23.7 million last year. Cash, cash equivalents, restricted cash, and short-term investments ended at about $261 million with no material debt. Management reaffirmed full-year 2025 revenue guidance of $165 million to $175 million, expects the year to be back-half weighted, and continues to expect a mid-teens percentage decline in Americas academia revenue, or roughly a high single-digit million-dollar impact versus 2024. Tariff exposure was described as a gross annualized impact in the low single-digit millions if fully absorbed.
Michael Egholm framed the quarter as a solid execution quarter in a choppy macro backdrop, emphasizing tighter operating discipline, improving forecast accuracy, and the use of the Standard BioTools Business System to drive rigor and accountability. He highlighted momentum in proteomics, recent product launches, and the Illumina partnership as strategic positives, while saying the company is navigating funding pressure and tariffs from a position of strength. His tone was confident but cautious: he repeatedly stressed that the company is not declaring victory, but believes the business is moving in the right direction.
Alex Kim focused on the financial bridge: revenue of $40.8 million, gross margin of 53.2%, non-GAAP operating expenses of $38.6 million, and adjusted EBITDA loss of $16.9 million. He said operating expenses were down 22% year over year and 10% sequentially, reflecting an additional $10 million annualized cost reduction, bringing total annualized cost reductions since the SomaLogic merger to $90 million. He also highlighted materially lower cash burn: total cash burn of $34 million versus $101 million last year, and adjusted cash burn of $31 million versus $47 million, while reiterating the $261 million cash balance and no material debt.
Analysts pressed on the full-year back-half weighting, the outlook for U.S. academia and government demand, the ramp from the Illumina partnership, and whether the $10 million cost action should improve EBITDA loss. Management said the back-half weighting is driven more by internal funnel metrics and larger projects than normal seasonality, and that U.S. academic demand remains under pressure with delayed instrument decisions and softer consumables orders. On Illumina, management said 2025 should see only moderate growth, with stronger traction expected in 2026 and beyond, while the $10 million cost action should flow through to improved adjusted EBITDA.
The company showed clear operating leverage: expenses, EBITDA loss, and cash burn all improved meaningfully while cash remained strong at $261 million. Management also pointed to improving instrument demand, traction in biopharma and international markets, and multiple new proteomics-related launches that could broaden the platform over time.
Revenue still declined 10% year over year, consumables and services were soft, and U.S. academia remains a headwind with delayed purchases and funding uncertainty. The Illumina partnership is still early, management expects only moderate revenue contribution in 2025, and tariff and macro volatility could add incremental pressure if costs cannot be passed through.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 10.9%
- Shares Outstanding
- 394.79M
- Float Shares
- 43.14M
of shares held by institutions
149 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Casdin Capital, LLC | 88.78M | 0 |
| Viking Global Investors LP | 58.65M | 0 |
| Mak Capital One LLC | 28.81M | ▲ 2.64M |
| Long Focus Capital Management, LLC | 23.50M | ▲ 7.48M |
| Vanguard Group Inc | 17.30M | ▲ 52.02K |
| Vanguard Capital Management LLC | 12.25M | ▼ 563.07K |
| Blackrock, Inc. | 8.25M | ▼ 16.50M |
| Hollow Brook Wealth Management LLC | 5.20M | ▼ 302.55K |
| Neuberger Berman Group LLC | 4.96M | ▲ 301.04K |
| Qube Research & Technologies Ltd | 4.82M | ▲ 4.12M |
| Geode Capital Management, LLC | 3.56M | ▼ 340.33K |
| Tikvah Management LLC | 3.55M | ▼ 94 |
Held by 67 ETFs
Biggest fund positions in LAB by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 5, 26 | Carey Thomas D. | buy | 75,000 |
| Aug 20, 26 | Mackay Sean | other | 25,729 |
| Aug 20, 26 | Kim Hanjoon Alex | other | 28,195 |
| Aug 20, 26 | Egholm Michael | other | 97,627 |
| Aug 3, 26 | Egholm Michael | other | 362,625 |
| Jul 23, 26 | Kim Hanjoon Alex | other | 202,476 |
| Jun 18, 26 | Carey Thomas D. | other | 99,116 |
| Jun 18, 26 | Carey Thomas D. | other | 263,884 |
| Jun 20, 26 | Mackay Sean | other | 500,000 |
| Jun 18, 26 | Witney Frank | other | 99,116 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our LAB coverage
Recent articles, reports, and earnings notes.
Want a deeper read on LAB?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Standard BioTools Stockholders Approve All Proposals Related to Merger with Treeline Biosciences and Sale of Mass Cytometry Business
globenewswire.com · Nov 19
ARCHIMED Life Science Tools & Services Completes Acquisition of Standard BioTools' Microfluidics Business, Now Biomark Scientific
globenewswire.com · Nov 3
Standard BioTools Announces Agreement to Sell Microfluidics Business to ARCHIMED
globenewswire.com · Oct 5
Standard BioTools Provides Update on Sale of Mass Cytometry Business
globenewswire.com · Sep 30
Are SMTI, LAB, ATKR, VAL Obtaining Fair Deals for their Shareholders?
gurufocus.com · Sep 11
Are SMTI, LAB, ATKR, VAL Obtaining Fair Deals for their Shareholders?
prnewswire.com · Sep 11
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Proxy and Looming Shareholder Merger Vote --VRME, VAL, LAB and FTHM
gurufocus.com · Sep 10
INVESTOR ALERT: The M&A Class Action Firm Launches Investigation of the Merger--IRDM, VRME, VAL and LAB
gurufocus.com · Sep 8
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
